drugset / Trial / NCT00511017

Doxercalciferol in Recurrent Pediatric Solid Tumors

NCT00511017

Phase 1 Terminated 1 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of doxercalciferol that can be given to pediatric patients with relapsed solid tumors. The safety of this drug will also be studied. Another goal is to measure the effect of the study drug on the blood levels of calcium and vitamin D.

Timeline

Start
2007-08
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxercalciferol Small molecule 0.05 ug/kg Oral

Indications